Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28166485 | 0.98 | MYC (0.41) | MYCXDHABCG2CHEK1ALDH1A1 | |
| SCHEMBL13461069 | 0.81 | MYC (0.49) | MYCXDHABCG2ALDH1A1NPY5R | |
| SCHEMBL31044560 | 0.80 | ALDH1A1 (0.33) | ALDH1A1KDM4ELMNASMN1; SMN2PTGS2 | |
| SCHEMBL4409572 | 0.80 | MYC (0.39) | MYCXDHABCG2CHEK1ALDH1A1 | |
| SCHEMBL22031557 | 0.80 | ALDH1A1 (0.33) | ALDH1A1KDM4ELMNASMN1; SMN2PTGS2 | |
| SCHEMBL3465367 | 0.77 | MYC (0.48) | MYCXDHABCG2ALDH1A1KDM4E | |
| SCHEMBL1145783 | 0.76 | MYC (0.36) | MYCXDHABCG2CHEK1ALDH1A1 | |
| SCHEMBL1145728 | 0.76 | MYC (0.36) | MYCXDHABCG2ALDH1A1KDM4E | |
| SCHEMBL2953977 | 0.75 | KDM4E (0.45) | MYCALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL2953973 | 0.75 | KDM4E (0.45) | MYCALDH1A1KDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | GENZYME CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| CN-121873041-A | Topiramate preparation method of special | 山东新时代药业有限公司 | 2026-04-17 | — | — | CN | disclosed |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| US-20250248975-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2025-08-07 | — | — | US | disclosed |
| EP-4583972-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Sionna Therapeutics Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2025-06-19 | — | — | US | disclosed |
| CN-119684267-A | Topiramate Special synthetic method | 山东新时代药业有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119684267-A | Topiramate Special synthetic method | 山东新时代药业有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024054840-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| US-20010036950-A1 | Potassium channel openers | CARROLL WILLIAM A (US) | 2001-11-01 | — | — | US | disclosed |
| US-6265417-B1 | MUSCLE RELAXANTS | ABBOTT LABORATORIES | 2001-07-24 | — | — | US | disclosed |
| US-5216170-A | Promoters of livestock; treatment of obesity | BAYER AKTIENGESELLSCHAFT (DE) | 1993-06-01 | — | — | US | disclosed |
| EP-0244728-B1 | USE OF HETEROARYLETHYL AMINES TO STIMULATE ANIMAL GROWTH, HETEROARYLETHYL AMINES AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1992-11-11 | — | — | EP | disclosed |
| US-5028617-A | Heteroarylethanol-pyridylalkylamines for controlling animal growth | BAYER AKTIENGESELLSCHAFT (DE) | 1991-07-02 | — | — | US | disclosed |
| EP-0379928-A2 | Aryl- and heteroarylethanol-pyridylalkylamines, process for their preparation and their use as performance stimulators by animals and as anti-adipositas agent | BAYER AG (DE) | 1990-08-01 | — | — | EP | disclosed |
| US-4863939-A | Heteroarylethylamine as production promoters in livestock | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0256420-A2 | Heteroarylethyl amines, process for their synthesis and their use in the promotion of animal performance | BAYER AG (DE) | 1988-02-24 | — | — | EP | disclosed |
| EP-0244728-A2 | Use of heteroarylethyl amines to stimulate animal growth, heteroarylethyl amines and process for their preparation | BAYER AG (DE) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | CFTR, ABCC3, ABCD3 | MYC 3239/4885XDH 2733/4885ABCG2 98/4885 |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | MYC 3239/4885XDH 2733/4885ABCG2 98/4885 |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | MYC 3039/4885XDH 2535/4885ABCG2 111/4885 |
| US-20010036950-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | MYC 3169/4885XDH 1507/4885ABCG2 1598/4885 |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | MYC 2020/4885XDH 3365/4885ABCG2 7/4885 |
| US-20250248975-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | MYC 2020/4885XDH 3365/4885ABCG2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.